1,085 results match your criteria: "Recurrent Respiratory Papillomatosis"

Objective: Narrow-band imaging (NBI) is considered useful for detecting respiratory papillomatosis. However, the choice between preoperative and intraoperative NBI depends on the facility. We investigated the usefulness of NBI and determined whether preoperative NBI can replace intraoperative NBI with a comparable detection rate.

View Article and Find Full Text PDF

HPV-related diseases in male patients: an underestimated conundrum.

J Endocrinol Invest

February 2024

Unit of Andrology and Reproductive Medicine, Department of Medicine, University of Padova, Padua, Italy.

Purpose: Human papillomavirus (HPV) infection is the most common sexually transmitted disease, in males and females worldwide. While the role of HPV in female diseases is well known and largely studied, males have negligibly been included in these programs, also because the proportion of women suffering and dying from HPV-related diseases is much larger than men. The aim of this review is to focus on HPV-related diseases in male patients.

View Article and Find Full Text PDF

Indications, Efficacy, Safety, and Clinical Outcomes of 585 nm Pulsed Dye Laser in Non-Malignant Laryngeal Lesions: A Systematic Review.

J Pers Med

September 2023

Young-Otolaryngologists of the International Federation of Oto-Rhino-Laryngological Societies (YO-IFOS), Research Study Group, 75000 Paris, France.

The objective of this manuscript was to review the indications, efficacy, and safety of a 585 nm pulsed dye laser (PDL) in non-malignant laryngeal lesions. Following the PRISMA statement recommendations, three independent authors searched for articles published in PubMed/MEDLINE, the Cochrane Library, Google Scholar, Scielo, and Web of Science. A bias analysis was performed following NICE guidance tools.

View Article and Find Full Text PDF

Recurrent laryngeal papillomatosis: multimodal therapeutic strategies. Literature review and multicentre retrospective study.

Acta Otorhinolaryngol Ital

April 2023

Department of Otolaryngology Head and Neck Surgery, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.

Objectives: Recurrent respiratory papillomatosis (RRP) is a benign, rare disease caused by Human Papilloma Virus (HPV) that can be divided into juvenile and adult forms. The course of the disease is variable, but is usually more aggressive in the juvenile form. The standard surgical treatment is represented by CO laser resection, although photoangiolytic lasers represent a valid alternative.

View Article and Find Full Text PDF

Environmental Sustainability: Waste Audit Comparison Operating Roomand In-Office Laryngeal Surgery.

Laryngoscope

February 2024

St Michaels Hospital, Department of Otolaryngology - Head and Neck Surgery, University of Toronto, Toronto, Canada.

Introduction: With vast improvements in imaging and endoscopic technology, there has been a massive shift towards in office procedures for various laryngeal disorders with significant health system and patient benefits. Another benefit which has yet to be investigated is the potential environmental effects and waste reduction of in-office laryngeal procedures over traditional operating room surgery.

Objectives: The purpose of this study is to perform a waste audit and compare the results between operating room and in-office laser laryngeal surgery.

View Article and Find Full Text PDF

Objective: This is a systematic review aimed to explore Cidofovir administration protocols, recurrence rates, and long-term effectiveness for severe cases of recurrent respiratory papillomatosis (RRP). The primary goal was to identify current practices, determine the preferred protocol, and assess the adjuvant therapy's ability to prevent long-term papilloma recurrence in juvenile and adult-onset disease.

Methods: The following databases were searched: Pubmed, Google Scholar (pages 1-10), EMBASE, Scopus, ISI (clarivate), Cochrane Library, and Journal Storage from 1996 to June 2022.

View Article and Find Full Text PDF

Aim: The objective of this study was to estimate and compare the cost-effectiveness of switching from a bivalent to a nonavalent human papillomavirus (HPV) vaccination program in Norway, incorporating all nonavalent vaccine-preventable HPV-related diseases and in the context of the latest cervical cancer screening program.

Methods: A well-established dynamic transmission model of the natural history of HPV infection and disease was adapted to the Norwegian population. We determined the number of cases of HPV-related diseases and subsequent number of deaths, and the economic burden of HPV-related disease under the current standard of care conditions of bivalent and nonavalent vaccinations of girls and boys aged 12 years.

View Article and Find Full Text PDF

Background: Evidence is lacking regarding the efficacy of transnasal humidified rapid insufflation ventilatory exchange (THRIVE) in tubeless anesthesia, especially in pediatric patients. This study aimed to evaluate the use of THRIVE for juvenile onset recurrent respiratory papillomatosis (JORRP) patients.

Methods: Twenty-eight children aged 2 to 12 years with JORRP, abnormal airways, and ASA physical status II-III that presented for surgical treatment under general anesthesia were included in this study.

View Article and Find Full Text PDF

Recent Developments in Human Papillomavirus (HPV) Vaccinology.

Viruses

June 2023

Institute of Infectious Disease and Molecular Medicine/SAMRC Gynaecological Cancer Research Centre/Division of Medical Virology, Department of Pathology, University of Cape Town, Cape Town 7925, South Africa.

Article Synopsis
  • HPV is linked to about 5% of cancers, particularly affecting the cervix, anus, and oropharynx, with HPV-16 being the most cancer-causing type.
  • There are six licensed HPV vaccines that primarily target the most dangerous types, with a focus on vaccinating children before they become sexually active, though catch-up campaigns for adults have shown benefits as well.
  • Gender-neutral vaccination can enhance overall community immunity and reduce infections in all genders, with ongoing research needed to understand the long-term effects of the vaccine, especially for people living with HIV.
View Article and Find Full Text PDF

Objectives: Pulmonary papillomatosis is a rare but severe manifestation of recurrent respiratory papillomatosis (RRP). Efficacy data of systemic bevacizumab for pulmonary RRP are limited. This study's objective was to characterize disease response of pulmonary RRP to systemic bevacizumab.

View Article and Find Full Text PDF

Objective: To compare the efficacy of two main treatment modalities of microdebrider and carbon dioxide laser excision for juvenile onset recurrent respiratory papillomatosis.

Methods: The retrospective study was conducted in May 2021 at the Combined Military Hospital, Kharian, Pakistan, and comprised data from July 1, 2007, to January 31, 2020, of patients of either gender aged 2-12 years who were treated for juvenile onset recurrent respiratory papillomatosis either with microdebrider excision in group A or carbon dioxide laser excision in group B. Extent and severity of disease was documented as per the Derkay-Coltrera grading system.

View Article and Find Full Text PDF

Renal Implications of Long-Term Systemic Bevacizumab for Recurrent Respiratory Papillomatosis.

Ann Otol Rhinol Laryngol

January 2024

Department of Otolaryngology - Head & Neck Surgery, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.

Background: Bevacizumab is a vascular endothelial growth factor (VEGF) inhibitor that is used off-label for select cases of recurrent respiratory papillomatosis (RRP) that are severe, involve the distal airway or lung parenchyma, and refractory to other forms of adjuvant therapy. However, there is limited safety data for the use of bevacizumab in children and VEGF inhibitors are reported to have a range of adverse renal effects, including hypertension, proteinuria, and thrombotic microangiopathy (TMA).

Case-diagnosis/treatment: This report describes a case of severe juvenile-onset RRP that had an exceptionally high operative burden that was refractory to several adjuvant treatment strategies (including intralesional cidofovir and subcutaneous pegylated interferon).

View Article and Find Full Text PDF

[Human papillomavirus prevalence and type distribution in Chinese juvenile-onset recurrent respiratory papillomatosis patients].

Zhonghua Liu Xing Bing Xue Za Zhi

June 2023

Department of Population Medicine, School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China Department of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

Article Synopsis
  • A study evaluated the prevalence and types of HPV in Chinese patients with juvenile-onset recurrent respiratory papillomatosis (JoRRP) by analyzing multiple research databases.
  • Nineteen studies involving 1,528 patients reported a high overall HPV prevalence of 92% and identified HPV6 and HPV11 as the most common types, with respective prevalences of 42.4% and 72.3%.
  • The research indicated consistent results across different subgroups and no evidence of publication bias, highlighting a need for further attention to HPV in the context of JoRRP.
View Article and Find Full Text PDF

Recurrent respiratory papillomatosis is a neoplastic disease caused by the human papillomavirus and characterized by the growth of exophytic proliferative lesions affecting the mucosa of the respiratory tract. This condition has a bimodal age distribution; the juvenile form affects those under 20 years of age, is more aggressive and presents multiple papillomatous lesions and high frequency of recurrence, compared to the adult form. Pulmonary involvement is rare and challenging to treat.

View Article and Find Full Text PDF

Laryngeal Suction tube: A Novel Technique for Tracheal Ventilation in an Obstructed Airway in a Child with Respiratory Papillomatosis.

Indian J Otolaryngol Head Neck Surg

June 2023

Jalan Universiti, 50603 Kuala Lumpur, WP Malaysia Department of Otorhinolaryngology, Faculty of Medicine, Universiti Malaya.

Background: Airway obstruction in a child requires expedite management in addition to comprehensive discussion between the Otolaryngology and Anaesthesiology team to formulate a treatment plan to ensure safe airway. Juvenile-onset recurrent respiratory papillomatosis (JORRP) is an exophytic benign laryngeal lesion which poses a great challenge when presented with respiratory distress.

Objective: This paper presents a novel, safe and cost-effective approach to temporary tracheal ventilation of the obstructed airway in a child with juvenile-onset recurrent respiratory papillomatosis using the laryngeal suction tube connected to general anaesthetic (GA) machine.

View Article and Find Full Text PDF

: Respiratory papillomatosis is one of the common benign lesions of the airway that is often difficult to treat and carries significant morbidity. Bevacizumab is a monoclonal antibody that acts upon vascular endothelial growth factor receptor and is known to have an effect in respiratory papillomatosis. This study aims to systematically review the literature on efficacy of intralesional Bevacizumab in juvenile onset respiratory papillomatosis.

View Article and Find Full Text PDF

The incidence of juvenile onset recurrent respiratory papillomatosis at Starship Children's Hospital before and after a national HPV vaccination programme: a retrospective review.

N Z Med J

May 2023

ORL Surgeon, Department of Paediatric Otorhinolaryngology, Starship Children's Hospital, Auckland, New Zealand; Senior Lecturer, Department of Surgery, The University of Auckland, Auckland, New Zealand.

Aim: To review and compare the incidence of juvenile onset recurrent respiratory papillomatosis (JRRP) at Starship Children's Hospital (SSH) before and after the introduction of a national HPV vaccination programme.

Methods: Patients treated for JRRP at SSH were identified retrospectively using ICD-10 code D14.1 over a 14-year period.

View Article and Find Full Text PDF

Preclinical Models of Laryngeal Papillomavirus Infection: A Scoping Review.

Laryngoscope

December 2023

Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, University of Wisconsin-Madison, Madison, Wisconsin, U.S.A.

Objective: Laryngeal human papillomavirus (HPV) infection causes recurrent respiratory papillomatosis (RRP) and accounts for up to 25% of laryngeal cancers. Lack of satisfactory preclinical models is one reason that treatments for these diseases are limited. We sought to assess the literature describing preclinical models of laryngeal papillomavirus infection.

View Article and Find Full Text PDF

Comparison of three different image enhancement systems for detection of laryngeal lesions.

J Laryngol Otol

January 2024

Department of Oto-Rhino-Laryngology, Plastic, Aesthetic and Reconstructive Head and Neck Surgery, University of Würzburg, Würzburg, Germany.

Article Synopsis
  • * Results showed that 50% of benign lesions, 41% of malignant lesions, and 9% of recurrent respiratory papillomatosis were confirmed accurately, with no significant differences in expert assessments across systems.
  • * The conclusion highlights that all three systems are effective for detecting laryngeal lesions, suggesting that expanding their availability can enhance oncological evaluations.
View Article and Find Full Text PDF

Objective: To evaluate the safety, immunogenicity, and efficacy of INO-3107, a DNA immunotherapy designed to elicit targeted T-cell responses against human papillomavirus (HPV) types 6 and 11, in adult patients with recurrent respiratory papillomatosis (RRP; NCT04398433).

Methods: Eligible patients required ≥2 surgical interventions for RRP in the year preceding dosing. INO-3107 was administered by intramuscular (IM) injection followed by electroporation (EP) on weeks 0, 3, 6, and 9.

View Article and Find Full Text PDF

Unlabelled: Recurrent respiratory papillomatosis (RRP) is a human papilloma virus (HPV)-driven benign neoplasm, affecting larynx, trachea, and even lung, leading to voice disorders, airway obstruction, and postobstructive pneumonia. Several case reports have documented the promising efficacy of intravenous bevacizumab in reducing the need for surgical intervention among RRP patients. Herein, we present our experience on systemic bevacizumab for pediatric patients with aggressive RRP.

View Article and Find Full Text PDF

Association between human papillomavirus particle production and the severity of recurrent respiratory papillomatosis.

Sci Rep

April 2023

Preeminent Medical Photonics Education and Research Center Institute for NanoSuit Research, Hamamatsu University School of Medicine, 1-20-1 Handayama Higashi-ku, Hamamatsu, Shizuoka, 431-3192, Japan.

Article Synopsis
  • Recurrent respiratory papillomatosis (RRP) severity correlates with human papillomavirus (HPV) particle production, indicating that HPV-positive cases require more surgical interventions than negative cases.
  • A study spanning from 2005 to 2021 analyzed samples from 29 patients and employed various techniques (like immunohistochemistry and advanced microscopy) to investigate the presence and behavior of HPV in RRP.
  • The findings suggest that L1 IHC could be a valuable tool for assessing RRP severity alongside traditional scoring methods, as higher L1 expression was linked to shorter surgical intervals and increased number of surgeries.
View Article and Find Full Text PDF

Recurrent Respiratory Papillomatosis (RRP)-Meta-analyses on the use of the HPV vaccine as adjuvant therapy.

NPJ Vaccines

April 2023

Dept of Haematology, Oncology and Palliative Medicine, Campus Klinikum Bielefeld Mitte, University Hospital OWL of Bielefeld University, Teutoburger Str. 50, 33604, Bielefeld, Germany.

Recurrent Respiratory Papillomatosis(RRP) is a rare disease with severe morbidity. Treatment is surgical. Prevailing viewpoint is that prophylactic HPV vaccines do not have therapeutic benefit due to their modus operandi.

View Article and Find Full Text PDF